These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

68 related items for PubMed ID: 6136688

  • 1. Activities of newer quinolones against legionella group organisms.
    Fallon RJ.
    Lancet; 1983 Aug 27; 2(8348):525. PubMed ID: 6136688
    [No Abstract] [Full Text] [Related]

  • 2. Activities of newer quinolones against Legionella group organisms.
    Greenwood D, Laverick A.
    Lancet; 1983 Jul 30; 2(8344):279-80. PubMed ID: 6135099
    [No Abstract] [Full Text] [Related]

  • 3. [Antibacterial activity in vitro of 10 quinolones against 20 strains of Legionella pneumophila].
    Deforges L, Fournet MP, Soussy CJ, Duval J.
    Pathol Biol (Paris); 1986 Jun 30; 34(5 Pt 2):631-3. PubMed ID: 3534757
    [Abstract] [Full Text] [Related]

  • 4. The in-vitro activity of moxifloxacin against Legionella species and the effects of medium on susceptibility test results.
    Ruckdeschel G, Dalhoff A.
    J Antimicrob Chemother; 1999 May 30; 43 Suppl B():25-9. PubMed ID: 10382872
    [Abstract] [Full Text] [Related]

  • 5. Susceptibility of Legionella spp. to quinolone derivatives and related organic acids.
    Ruckdeschel G, Ehret W, Ahl A.
    Eur J Clin Microbiol; 1984 Aug 30; 3(4):373. PubMed ID: 6489330
    [No Abstract] [Full Text] [Related]

  • 6. Activity of quinolones against Legionellaceae.
    Pohlod DJ, Saravolatz LD.
    J Antimicrob Chemother; 1986 Apr 30; 17(4):540-1. PubMed ID: 3710961
    [No Abstract] [Full Text] [Related]

  • 7. In-vitro sensitivity of legionellas, meningococci and mycoplasmas to ciprofloxacin and enoxacin.
    Fallon RJ, Brown WM.
    J Antimicrob Chemother; 1985 Jun 30; 15(6):787-9. PubMed ID: 3161857
    [No Abstract] [Full Text] [Related]

  • 8. Antibacterial activities of gemifloxacin, levofloxacin, gatifloxacin, moxifloxacin and erythromycin against intracellular Legionella pneumophila and Legionella micdadei in human monocytes.
    Baltch AL, Bopp LH, Smith RP, Michelsen PB, Ritz WJ.
    J Antimicrob Chemother; 2005 Jul 30; 56(1):104-9. PubMed ID: 15941776
    [Abstract] [Full Text] [Related]

  • 9. Sensitivity and resistance of Legionella pneumophila to some antibiotics and combinations of antibiotics.
    Moffie BG, Mouton RP.
    J Antimicrob Chemother; 1988 Oct 30; 22(4):457-62. PubMed ID: 3204075
    [Abstract] [Full Text] [Related]

  • 10. Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp.
    Dubois J, St-Pierre C.
    J Antimicrob Chemother; 2000 Apr 30; 45 Suppl 1():41-6. PubMed ID: 10824031
    [Abstract] [Full Text] [Related]

  • 11. In vitro activity of pazufloxacin, tosufloxacin and other quinolones against Legionella species.
    Higa F, Akamine M, Haranaga S, Tohyama M, Shinzato T, Tateyama M, Koide M, Saito A, Fujita J.
    J Antimicrob Chemother; 2005 Dec 30; 56(6):1053-7. PubMed ID: 16260445
    [Abstract] [Full Text] [Related]

  • 12. In-vitro activity of RP 59500, a new synergic antibacterial agent, against Legionella spp.
    Dubois J, Joly JR.
    J Antimicrob Chemother; 1992 Jul 30; 30 Suppl A():77-81. PubMed ID: 1399954
    [Abstract] [Full Text] [Related]

  • 13. In vitro activities of ciprofloxacin, ofloxacin, norfloxacin and rosoxacin compared with cinoxacin and trimethoprim.
    Digranes A, Dibb WL, Benonisen E.
    Chemotherapy; 1985 Jul 30; 31(6):466-71. PubMed ID: 2934234
    [Abstract] [Full Text] [Related]

  • 14. Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing.
    Stout JE, Sens K, Mietzner S, Obman A, Yu VL.
    Int J Antimicrob Agents; 2005 Apr 30; 25(4):302-7. PubMed ID: 15784309
    [Abstract] [Full Text] [Related]

  • 15. The effects of single and combined antibiotics on the growth of Legionella pneumophila using time-kill studies.
    Barker JE, Farrell ID.
    J Antimicrob Chemother; 1990 Jul 30; 26(1):45-53. PubMed ID: 2211446
    [Abstract] [Full Text] [Related]

  • 16. Bacterial resistance to norfloxacin and other newer quinolones: pattern and prospects.
    Nalin DR.
    Eur J Cancer Clin Oncol; 1988 Jul 30; 24 Suppl 1():S55-61. PubMed ID: 3280327
    [No Abstract] [Full Text] [Related]

  • 17. Frequency and expression of mutational resistance to the 4-quinolone antibacterials.
    Smith JT.
    Scand J Infect Dis Suppl; 1986 Jul 30; 49():115-23. PubMed ID: 3547618
    [Abstract] [Full Text] [Related]

  • 18. In-vitro activity of a new oral streptogramin, RPR 106972, alone and in combination with rifampicin or ciprofloxacin against Legionella spp.
    Pendland SL, Killian AD, Woodward JG, Rodvold KA.
    J Antimicrob Chemother; 1997 May 30; 39(5):651-3. PubMed ID: 9184367
    [Abstract] [Full Text] [Related]

  • 19. The in-vitro activities of enoxacin and ofloxacin compared with that of ciprofloxacin.
    King A, Shannon K, Phillips I.
    J Antimicrob Chemother; 1985 May 30; 15(5):551-8. PubMed ID: 3159712
    [Abstract] [Full Text] [Related]

  • 20. In-vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis.
    Berlin OG, Young LS, Bruckner DA.
    J Antimicrob Chemother; 1987 May 30; 19(5):611-5. PubMed ID: 3112095
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.